GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076459" target="_blank" >RIV/65269705:_____/22:00076459 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/22:00126321
Result on the web
<a href="https://reader.elsevier.com/reader/sd/pii/S1043276022001229?token=7982FCC761ED2E64F458459E6FB9C0091AC18519E32A6D640F8F27DFAE6187F262A687F85864600C15E3367ACC54E092&originRegion=eu-west-1&originCreation=20221122134927" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S1043276022001229?token=7982FCC761ED2E64F458459E6FB9C0091AC18519E32A6D640F8F27DFAE6187F262A687F85864600C15E3367ACC54E092&originRegion=eu-west-1&originCreation=20221122134927</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.tem.2022.06.005" target="_blank" >10.1016/j.tem.2022.06.005</a>
Alternative languages
Result language
angličtina
Original language name
GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
Original language description
Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impair-ment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Trends in Endocrinology and Metabolism
ISSN
1043-2760
e-ISSN
1879-3061
Volume of the periodical
33
Issue of the periodical within the volume
9
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
628-638
UT code for WoS article
000877913500003
EID of the result in the Scopus database
2-s2.0-85134850918